This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Further Clinical Evaluation

WILLIAM C. KUZELL, M.D.; RALPH W. SCHAFFARZICK, M.D.; W. EDWARD NAUGLER, M.D.; GUY GAUDIN, M.D.; ELDON A. MANKLE, B.A.

AMA Arch Intern Med. 1953;92(5):646-661.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THIS REPORT evaluates the use of phenylbutazone (Butazolidin) for 800 patients with a variety of diseases. It covers a period of 30 months, from November 1950 to May 1953. During the first eight months phenylbutazone was used with equal parts of aminopyrine as a mixture known in the United States as Butapyrin and in Europe as Irgapyrin. Phenylbutazone was first synthesized by H. Stenzl in the laboratories of the J. R. Geigy Company, Basle, Switzerland. The chemistry and pharmacology of this pyrazole have been reported elsewhere.¹

Since numerous clinical reports have described the therapeutic benefits of Butapyrin in rheumatic diseases, it was felt desirable to evaluate the results of using phenylbutazone alone. At the request of the authors this compound was made available for clinical trials. After July 1951 phenylbutazone was used alone orally and intramuscularly. In previous communications¹ the therapeutic value and the toxicity of phenylbutazone and . . . [Full Text PDF of this Article]

Author Affiliations
SAN FRANCISCO

From the Department of Pharmacology and Therapeutics, Rheumatic Disease Study Group, Stanford University School of Medicine.

Footnotes
Dr. Windsor C. Cutting, Professor of Pharmacology and Therapeutics, gave advice.

This paper was presented before the American Rheumatism Association, New York, May 29, 1953.

The handling of cur data was facilitated by the use of punched cards. Dr. L. E. Moses, of the Department of Statistics, helped us in the statistical treatment of the data.

Dr. Albert Hemming, of Geigy Pharmaceuticals, New York, gave advice during the course of this study, and Grants-in-aid were received from Geigy Pharmaceuticals, Division of Geigy Company, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?